| Assessment Status | Rapid Review Complete |
| Drug | Telavancin |
| Brand | Vibativ® |
| Indication | For the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumomia, known or suspended to be caused by methicillin-resistant Staphylococcus aureas (MRSA). Vabitiv® should be used only in situations where it is known or suspected that other alternatives are not suitable. |
| Assessment Process | |
| Rapid review completed | 13/01/2015 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended |
Latest NCPE Advice
Teriflunomide (Aubagio®)
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Teriflunomide |
| Brand | Aubagio® |
| Indication | For the first line treatment of adult patients with relapsing remitting multiple sclerosis (MS). |
| Assessment Process | |
| Rapid review commissioned | 27/08/2013 |
| Rapid review completed | 20/09/2013 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full HTA commissioned by the HSE | 25/11/2013 |
| NCPE assessment completed | 19/06/2014 |
| NCPE assessment outcome | Reimbursement Not Recommended. |
The NCPE does not recommend reimbursement of teriflunomide (Aubagio®) at the current price.
The HSE has approved reimbursement following price negotiations-September 2014
Tezepelumab (Tezspire®). HTA ID: 23025
| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23025 |
| Drug | Tezepelumab |
| Brand | Tezspire® |
| Indication | Tezepelumab (Tezspire®) is indicated as add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma, who are inadequately controlled despite high-dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment. |
| Assessment Process | |
| Rapid review commissioned | 10/05/2023 |
| Rapid review completed | 15/06/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that tezepelumab not be considered for reimbursement at the submitted price*. |
| Full HTA commissioned by the HSE | 01/02/2024 |
| Pre-submission consultation with Applicant | 05/03/2024 |
| Full submission received from Applicant | 04/06/2024 |
| Preliminary review sent to Applicant | 13/03/2025 |
| NCPE assessment re-commenced | 11/04/2025 |
| Factual accuracy sent to Applicant | 11/06/2025 |
| NCPE assessment re-commenced | 17/06/2025 |
| NCPE assessment completed | 01/07/2025 |
| NCPE assessment outcome | The NCPE recommends that tezepelumab (Tezspire®) not be considered for reimbursement as add-on treatment for adults and adolescents 12 years and older with severe asthma with blood eosinophil levels < 300 cells per microlitre, who are inadequately controlled despite high-dose inhaled corticosteroids plus another maintenance treatment (subpopulation of the licensed population)*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. December 2025
Ticagrelor (Brilique®)
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Ticagrelor |
| Brand | Brilique® |
| Indication | For the prevention of atherothrombotic events in adult patients with Acute Coronary Syndrome (ACS) including patients managed medically, and those who are managed with PCI (Percutaneous Coronary Intervention) or CABG (Coronary Artery Bypass Graft). |
| Assessment Process | |
| Rapid review commissioned | 25/11/2010 |
| Rapid review completed | 20/01/2011 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full HTA commissioned by the HSE | 27/07/2011 |
| NCPE assessment completed | 10/10/2011 |
| NCPE assessment outcome | Reimbursement Recommended |
We consider Ticagrelor (Brilique®) a cost effective therapy for the prevention of atherothrombotic events in adult patients with ACS including patients managed medically and those managed with PCI or CABG.
Ticagrelor (Brilique®) in combination with acetylsalicyclic acid
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Ticagrelor |
| Brand | Brilique® |
| Indication | Co-administered with acetylsalicylic acid (ASA), for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event. |
| Assessment Process | |
| Rapid review commissioned | 29/02/2016 |
| Rapid review completed | 04/05/2016 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
Not considered cost-effective due to non-submission of full pharmacoeonomic evaluation
Tildrakizumab (Ilumetri®). HTA ID: 19029
| Assessment Status | Assessment process complete |
| HTA ID | 19029 |
| Drug | Tildrakizumab |
| Brand | Ilumetri® |
| Indication | For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 30/07/2019 |
| Rapid review completed | 28/08/2019 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tildrakizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
| Full HTA commissioned by the HSE | 19/05/2020 |
| Pre-submission consultation with Applicant | 08/02/2021 |
| Full submission received from Applicant | 04/05/2021 |
| Preliminary review sent to Applicant | 20/07/2021 |
| NCPE assessment re-commenced | 23/08/2021 |
| Factual accuracy sent to Applicant | 15/10/2021 |
| NCPE assessment re-commenced | 03/11/2021 |
| NCPE assessment completed | 25/11/2021 |
| NCPE assessment outcome | The NCPE recommends that tildrakizumab (Ilumetri®), for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy and who have failed treatment with non-biologic therapies and first-line biologic treatment with adalimumab, be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations May 2022.
Tirbanibulin (Klisyri®). HTA ID: 21054
| Assessment Status | Rapid Review Complete |
| HTA ID | 21054 |
| Drug | Tirbanibulin |
| Brand | Klisyri® |
| Indication | For the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults. |
| Assessment Process | |
| Rapid review commissioned | 15/11/2021 |
| Rapid review completed | 30/11/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that tirbanibulin not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Tirzepatide (Mounjaro®). HTA ID: 24003
| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 24003 |
| Drug | Tirzepatide |
| Brand | Mounjaro® |
| Indication | Tirzepatide (Mounjaro®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in addition to other medicinal products for the treatment of diabetes. |
| Rapid review commissioned | 24/01/2024 |
| Rapid review completed | 06/02/2024 |
| Full pharmacoeconomic assessment commissioned by HSE | 01/03/2024 |
| Pre-submission consultation with Applicant | 30/04/2024 |
| Full submission received from Applicant | 10/04/2025 |
| Assessment process on hold as updated submission required | 02/05/2025 |
| NCPE assessment recommenced | 23/08/2025 |
| Preliminary review sent to Applicant | 19/09/2025 |
| NCPE assessment recommenced | 06/11/2025 |
| Factual accuracy check sent to Applicant | 09/01/2026 |
| NCPE assessment recommenced | 16/01/2026 |
| NCPE assessment completed | 09/02/2026 |
| NCPE assessment outcome | The NCPE recommends that tirzepatide for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise (i) as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; (ii) in addition to other medicinal products for the treatment of diabetes; be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Tisagenlecleucel (Kymriah®) for DLBCL
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Tisagenlecleucel |
| Brand | Kymriah® |
| Indication | For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 19/08/2018 |
| Rapid review completed | 18/10/2018 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care. |
| Full HTA commissioned by the HSE | 22/10/2018 |
| Pre-submission consultation with Applicant | 06/11/2018 |
| Full submission received from Applicant | 23/01/2019 |
| Preliminary review sent to Applicant | 28/05/2019 |
| NCPE assessment re-commenced | 26/06/2019 |
| Factual accuracy sent to Applicant | 27/08/2019 |
| NCPE assessment re-commenced | 04/09/2019 |
| NCPE assessment completed | 20/09/2019 |
| NCPE assessment outcome | The NCPE recommends that tisagenlecleucel (Kymriah®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.* |
This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations July 2021.
Tisagenlecleucel (Kymriah®) for pALL
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Tisagenlecleucel |
| Brand | Kymriah® |
| Indication | For the treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse. |
| Assessment Process | |
| Rapid review commissioned | 19/09/2018 |
| Rapid review completed | 19/10/2018 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care. |
| Full HTA commissioned by the HSE | 22/10/2018 |
| Pre-submission consultation with Applicant | 06/11/2018 |
| Full submission received from Applicant | 30/01/2019 |
| Preliminary review sent to Applicant | 11/04/2019 |
| NCPE assessment re-commenced | 10/05/2019 |
| Factual accuracy sent to Applicant | 23/07/2019 |
| NCPE assessment re-commenced | 01/08/2019 |
| NCPE assessment completed | 27/08/2019 |
| NCPE assessment outcome | The NCPE recommends that tisagenlecleucel (Kymriah®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations July 2021.
Tislelizumab (Tevimbra®) NSQ NSCLC. HTA ID 26009
| Assessment Status | Rapid Review Complete |
| HTA ID | 26009 |
| Drug | Tislelizumab |
| Brand | Tevimbra® |
| Indication | Tislelizumab (Tevimbra®) in combination with pemetrexed and platinum containing chemotherapy for the first-line treatment of adult patients with non-squamous non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥ 50% of tumour cells with no EGFR or ALK positive mutations and who have: • locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or • metastatic NSCLC. |
| Assessment Process | |
| Rapid review commissioned | 11/03/2026 |
| Rapid review completed | 10/04/2026 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that tislelizumab (Tevimbra®) not be considered for reimbursement at the submitted price. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here
Tislelizumab (Tevimbra®) SQ NSCLC. HTA ID 26010
| Assessment Status | Rapid Review Complete |
| HTA ID | 26010 |
| Drug | Tislelizumab |
| Brand | Tevimbra® |
| Indication | Tislelizumab (Tevimbra®) in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of adult patients with squamous non-small cell lung cancer (NSCLC) who have: • locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or • metastatic NSCLC. |
| Assessment Process | |
| Rapid review commissioned | 11/03/2026 |
| Rapid review completed | 10/04/2026 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that tislelizumab (Tevimbra®)not be considered for reimbursement at the submitted price. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be foundhere
Further information on the status of this decision may be found here
Tislelizumab (Tevimbra®). HTA ID 25033
| Assessment Status | Rapid Review Complete |
| HTA ID | 25033 |
| Drug | Tislelizumab |
| Brand | Tevimbra® |
| Indication | Tislelizumab (Tevimbra®) is indicated in combination with platinum-based chemotherapy for the first-line treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma (OSCC) whose tumours express programmed death-ligand (PD-L1) with a tumour area positivity (TAP) score ≥ 5%. |
| Assessment Process | |
| Rapid review commissioned | 08/05/2025 |
| Rapid review completed | 09/06/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that tislelizumab not be considered for reimbursement at the submitted price. |
This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here.
Further information on the status of this decision may be found here.
Tislelizumab (Tevimbra®). HTA ID: 25070
| Assessment Status | Rapid Review Complete |
| HTA ID | 25070 |
| Drug | Tislelizumab |
| Brand | Tevimbra® |
| Indication | Tislelizumab (Tevimbra®) is indicated in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adult patients with human epidermal growth factor (HER2)-negative locally advanced unresectable or metastatic gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours express programmed death-ligand 1 (PD-L1) with a tumour area positivity (TAP) score ≥ 5. |
| Assessment Process | |
| Rapid review commissioned | 11/12/2025 |
| Rapid review completed | 18/12/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that tislelizumab not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here.
Further information on the status of this decision may be found here.
Tislelizumab (Tevimbra®). HTA ID: 26021
| Assessment Status | Rapid Review Complete |
| HTA ID | 26021 |
| Drug | Tislelizumab |
| Brand | Tevimbra® |
| Indication | Tislelizumab (Tevimbra®) in combination with platinum containing chemotherapy (ChT) is indicated as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for the treatment of adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. |
| Assessment Process | |
| Rapid review commissioned | 12/05/2026 |
| Rapid review completed | 17/06/2026 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that tislelizumab in combination with platinum-containing ChT for this indication not be considered for reimbursement at the proposed price. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here
Tivozanib (Fotivda®)
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Tivozanib |
| Brand | Fotivda® |
| Indication | For the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC. |
| Assessment Process | |
| Rapid review commissioned | 09/01/2019 |
| Rapid review completed | 24/01/2019 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tivozanib compared with the current standard of care. |
The HSE has approved reimbursement following confidential price negotiations August 2019.
Tixagevimab /cilgavimab (Evusheld®). HTA ID: 22015
| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22015 |
| Drug | Tixagevimab /cilgavimab |
| Brand | Evusheld® |
| Indication | For the pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg. |
| Assessment Process | |
| Rapid review commissioned | 09/03/2022 |
| Rapid review completed | 11/04/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tixagevimab/cilgavimab compared with the current standard of care. |
| Full HTA commissioned by the HSE | 29/04/2022 |
| Pre-submission consultation with Applicant | 29/06/2022 |
| Full submission received from Applicant | 16/08/2022 |
| Preliminary review sent to Applicant | 28/10/2022 |
| NCPE assessment re-commenced | 28/11/2022 |
| Factual accuracy sent to Applicant | 12/12/2022 |
| NCPE assessment re-commenced | 19/12/2022 |
| NCPE assessment completed | 21/12/2022 |
| NCPE assessment outcome | The NCPE recommends that tixagevimab/cilgavimab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
Tixagevimab/cilgavimab (Evusheld®).HTA ID: 22074
| Assessment Status | Rapid Review Complete |
| HTA ID | 22074 |
| Drug | Tixagevimab/cilgavimab |
| Brand | Evusheld® |
| Indication | Is indicated for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. |
| Assessment Process | |
| Rapid review commissioned | 12/12/2022 |
| Rapid review completed | 25/01/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tixagevimab/cilgavimab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Tobramycin (TOBI Podhaler®)
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Tobramycin |
| Brand | TOBI Podhaler® |
| Indication | For the suppressive therapy of chronic pulmonary infection due to Ps aeruginosa in adults and children aged 6 years and older with CF. |
| Assessment Process | |
| Rapid review commissioned | 03/11/2010 |
| Rapid review completed | 29/11/2010 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended |
Tocilizumab SC (RoActemra®)
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Tocilizumab SC |
| Brand | RoActemra® |
| Indication | For the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate. |
| Assessment Process | |
| Rapid review commissioned | 28/04/2014 |
| Rapid review completed | 16/07/2014 |
| Rapid review outcome | Full pharmacoeconomic assessment recommended at the submitted price. |
The HSE has approved reimbursement following confidential price negotiation.
Tofacitinib (Xeljanz®) for active polyarticular juvenile idiopathic arthritis. HTA ID: 21034
| Assessment Status | Rapid Review Complete |
| HTA ID | 21034 |
| Drug | Tofacitinib |
| Brand | Xeljanz® |
| Indication | For the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive or negative polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis in patients 2 years of age and older, who have responded inadequately to previous therapy with DMARDs. Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. |
| Assessment Process | |
| Rapid review commissioned | 18/08/2021 |
| Rapid review completed | 08/09/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tofacitinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations March 2022.
Tofacitinib (Xeljanz®) for ankylosing spondylitis. HTA ID: 22005
| Assessment Status | Rapid Review Complete |
| HTA ID | 22005 |
| Drug | Tofacitinib |
| Brand | Xeljanz® |
| Indication | For the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy. |
| Assessment Process | |
| Rapid review commissioned | 07/02/2022 |
| Rapid review completed | 08/03/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that tofacitinib not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Tofacitinib (Xeljanz®) for Ulcerative Colitis
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Tofacitinib |
| Brand | Xeljanz® |
| Indication | For the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy (i.e. corticosteroids, azathioprine, 6-mercaptopurine) or a biologic agent (i.e. TNF inhibitor). |
| Assessment Process | |
| Rapid review commissioned | 16/07/2018 |
| Rapid review completed | 18/09/2018 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tofacitinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations November 2020.
Tolvaptan (Jinarc®)
| Assessment Status | Assessment process complete |
| HTA ID | – |
| Drug | Tolvaptan |
| Brand | Jinarc® |
| Indication | To slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1-3 at initiation of treatment with evidence of rapidly progressing disease. |
| Assessment Process | |
| Rapid review commissioned | 04/01/2016 |
| Rapid review completed | 12/01/2016 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 27/01/2017 |
| Full pharmacoeconomic assessment re-commissioned by HSE | 14/08/2017 |
| Pre-submission consultation with Applicant | 18/09/2017 |
| Full submission received from Applicant | 06/02/2018 |
| Preliminary review sent to Applicant | 03/04/2018 |
| NCPE assessment re-commenced | 14/05/2018 |
| Follow-up to preliminary review sent to Applicant | 03/07/2018 |
| NCPE assessment re-commenced | 23/07/2018 |
| Factual accuracy sent to applicant | 27/08/2018 |
| NCPE assessment re-commenced | 06/09/2018 |
| NCPE assessment completed | 13/09/2018 |
| NCPE assessment outcome | The NCPE recommends that tolvaptan not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations; May 2019
Toripalimab (Loqtorzi®) for metastatic oesophageal squamous cell carcinoma. HTA ID: 26031
| Assessment Status | Rapid Review Complete |
| HTA ID | 26031 |
| Drug | Toripalimab for metastatic oesophageal squamous cell carcinoma |
| Brand | Loqtorzi® |
| Indication | Toripalimab (Loqtorzi®) in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. |
| Assessment Process | |
| Rapid review commissioned | 30/06/2026 |
| Rapid review completed | 22/07/2026 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of toripalimab (Loqtorzi®) for this indication compared with the current standard of care. |
Toripalimab (Loqtorzi®). HTA ID: 26022
| Assessment Status | Rapid Review Complete |
| HTA ID | 26022 |
| Drug | Toripalimab |
| Brand | Loqtorzi® |
| Indication | Toripalimab (Loqtorzi®) in combination with cisplatin and gemcitabine is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. |
| Assessment Process | |
| Rapid review commissioned | 12/05/2026 |
| Rapid review completed | 09/06/2026 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of toripalimab (Loqtorzi®) compared with the current standard of care. |
Tralokinumab (Adtralza®). HTA ID: 21028
| Assessment Status | Rapid Review Complete |
| HTA ID | 21028 |
| Drug | Tralokinumab |
| Brand | Adtralza® |
| Indication | For the treatment of moderate to severe atopic dermatitis in adults who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 29/06/2021 |
| Rapid review completed | 29/07/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that tralokinumab should not be considered for reimbursement at the submitted price.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations March 2022.
Tramadol hydrochloride/dexketoprofen (Skudexa®)
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Tramadol hydrochloride/dexketoprofen |
| Brand | Skudexa® |
| Indication | For the symptomatic short-term treatment of moderate to severe acute pain in adult patients whose pain is considered to require a combination of tramadol and dexketoprofen. |
| Assessment Process | |
| Rapid review commissioned | 17/10/2017 |
| Rapid review completed | 01/12/2017 |
| Rapid review outcome | Reimursement not recommended at the submitted price |
Trametinib (Mekinist®)
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Trametinib |
| Brand | Mekinist® |
| Indication | For the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. |
| Assessment Process | |
| Rapid review commissioned | 27/11/2015 |
| Rapid review completed | 22/12/2015 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full HTA commissioned by the HSE | 27/07/2016 |
| NCPE assessment completed | 15/03/2017 |
| NCPE assessment outcome | Reimbursement Not Recommended at the submitted price. |
The HSE has approved reimbursement following confidential price negotiations; April 2018.
Trastuzumab emtansine (Kadcyla®)
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Trastuzumab emtansine |
| Brand | Kadcyla® |
| Indication | For the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and taxane, separately or in combination. |
| Assessment Process | |
| Rapid review commissioned | 25/09/2013 |
| Rapid review completed | 24/10/2013 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full HTA commissioned by the HSE | 05/02/2014 |
| NCPE assessment completed | 30/06/2014 |
| NCPE assessment outcome | Reimbursement Not Recommended. |
The NCPE do not recommend reimbursement of trastuzumab emtansine (Kadcyla®) at the submitted price.
December 2015
The HSE has approved reimbursement following confidential price negotiations.
Trastuzumab emtansine (Kadcyla®) HTA ID: 20002
| Assessment Status | Assessment process complete |
| HTA ID | 20002 |
| Drug | Trastuzumab emtansine |
| Brand | Kadcyla® |
| Indication | As a single agent, for the adjuvant treatment of adults with HER2-positive, early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy. |
| Assessment Process | |
| Rapid review commissioned | 20/01/2020 |
| Rapid review completed | 27/02/2020 |
| Rapid review outcome | A full HTA is recommended to assess the clinical and cost effectiveness of trastuzumab emtansine compared with the current standard of care. |
| Full HTA commissioned by the HSE | 04/03/2020 |
| Pre-submission consultation with Applicant | 31/03/2020 |
| Full submission received from Applicant | 08/06/2020 |
| Preliminary review sent to Applicant | 29/10/2020 |
| NCPE assessment re-commenced | 30/11/2020 |
| Factual accuracy sent to Applicant | 11/02/2021 |
| NCPE assessment re-commenced | 17/02/2021 |
| NCPE assessment completed | 12/03/2021 |
| NCPE assessment outcome | The NCPE recommends that trastuzumab emtansine (Kadcyla®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations December 2021.
Trientine Tetrahydrochloride (TETA 4HCL) – Cuprior®
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Trientine Tetrahydrochloride (TETA 4HCL) |
| Brand | Cuprior® |
| Indication | For the treatment of Wilson’s disease in adults and children ≥ five years intolerant to D-penicillamine therapy. |
| Assessment Process | |
| Rapid review commissioned | 19/08/2019 |
| Rapid review completed | 09/10/2019 |
| Rapid review outcome | A full HTA is not recommended.The NCPE recommends that trientine tetrahydrochloride (TETA 4HCl) not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement following confidential price negotiations, March 2020.
Trifluridine/tipiracil (Lonsurf®)
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Trifluridine/tipiracil |
| Brand | Lonsurf® |
| Indication | For the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents. |
| Assessment Process | |
| Rapid review commissioned | 10/06/2016 |
| Rapid review completed | 11/07/2016 |
| Rapid review outcome | Full pharmacoeconomic assessment recommended at the submitted price. |
Tucatinib (Tukysa®). HTA ID: 22058
| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22058 |
| Drug | Tucatinib |
| Brand | Tukysa® |
| Indication | In combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer wo have received at least two prior anti-HER2 treatment regimens. |
| Assessment Process | |
| Rapid review commissioned | 23/08/2022 |
| Rapid review completed | 20/09/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tucatinib compared with the current standard of care. |
| Full HTA commissioned by the HSE | 28/09/2022 |
| Pre-submission consultation with Applicant | 12/12/2023 |
| Full submission received from Applicant | 14/03/2024 |
| Preliminary review sent to Applicant | 06/12/2024 |
| NCPE assessment re-commenced | 07/03/2025 |
| Follow-up to preliminary review sent to Applicant | 10/04/2025 |
| NCPE assessment re-commenced | 23/05/2025 |
| Additional follow-up to Preliminary Review sent to Applicant | 23/07/2025 |
| NCPE assessment re-commenced | 01/08/2025 |
| Factual accuracy sent to Applicant | 11/08/2025 |
| NCPE assessment re-commenced | 18/08/2025 |
| NCPE assessment completed | 25/09/2025 |
| NCPE assessment outcome | The NCPE recommends that tucatinib not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013
Upadacitinib (Rinvoq®) for giant cell arteritis. HTA ID: 25023
| Assessment Status | Rapid Review Complete |
| HTA ID | 25023 |
| Drug | Upadacitinib |
| Brand | Rinvoq® |
| Indication | Upadacitinib is indicated for the treatment of giant cell arteritis in adult patients. |
| Assessment Process | |
| Rapid review commissioned | 25/03/2025 |
| Rapid review completed | 17/04/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of upadacitinib compared with the current standard of care. |
Ustekinumab (Stelara®)
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Ustekinumab |
| Brand | Stelara® |
| Indication | For the treatment of moderate to severe psoriasis. |
| Assessment Process | |
| Full submission received from Applicant | 01/07/2009 |
| NCPE assessment completed | 01/11/2009 |
| NCPE assessment outcome | Reimbursement recommended. |
We consider ustekinumab cost effective for the treatment of moderate to severe plaque psoriasis in the Irish healthcare setting.
Vedolizumab (Entyvio®) in Crohn’s Disease
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Vedolizumab |
| Brand | Entyvio® |
| Indication | For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. |
| Assessment Process | |
| Rapid review commissioned | 12/09/2014 |
| Rapid review completed | 01/10/2014 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 02/04/2015 |
| NCPE assessment completed | 13/11/2015 |
| NCPE assessment outcome | Reimbursement Not Recommended at the submitted price. |
The HSE has approved reimbursement following confidential price negotiations October 2017.
Vedolizumab (Entyvio®) in Ulcerative Colitis
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Vedolizumab |
| Brand | Entyvio® |
| Indication | For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. |
| Assessment Process | |
| Rapid review commissioned | 12/09/2014 |
| Rapid review completed | 10/10/2014 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 05/03/2015 |
| NCPE assessment completed | 13/11/2015 |
| NCPE assessment outcome | Reimbursement Not Recommended at the submitted price. |
The HSE has approved reimbursement following confidential price negotiations October 2017.
Vemurafenib (Zelboraf®)
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Vemurafenib |
| Brand | Zelboraf® |
| Indication | For the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. |
| Assessment Process | |
| Rapid review commissioned | 23/12/2011 |
| Rapid review completed | 04/01/2012 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 04/05/2012 |
| NCPE assessment outcome | Reimbursement not recommended at the submitted price |
The NCPE believe that, at the submitted price, vemurafenib (Zelboraf®) is not cost effective for this indication
September 2014
The HSE has approved reimbursement following confidential price negotiations.
Venetoclax (Venclyxto®) in combination with obinutuzumab (Gazyvaro®). HTA ID: 20046
| Assessment Status | Assessment process complete |
| HTA ID | 20046 |
| Drug | Venetoclax in combination with obinutuzumab |
| Brand | Venclyxto® / Gazyvaro® |
| Indication | For the treatment of adult patients with previously untreated chronic lymphocytic leukaemia. |
| Assessment Process | |
| Rapid review commissioned | 07/10/2020 |
| Rapid review completed | 22/10/2020 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of venetoclax in combination with obinutuzumab compared with the current standard of care. |
| Full HTA commissioned by the HSE | 27/10/2020 |
| Pre-submission consultation with Applicant | 30/11/2020 |
| Full submission received from Applicant | 05/02/2021 |
| Preliminary review sent to Applicant | 31/05/2021 |
| NCPE assessment re-commenced | 30/06/2021 |
| Factual accuracy sent to Applicant | 27/07/2021 |
| NCPE assessment re-commenced | 04/08/2021 |
| NCPE assessment completed | 17/08/2021 |
| NCPE assessment outcome | The NCPE recommends that venetoclax in combination with obinutuzumab be considered for reimbursement.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medicinal Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations March 2022.
Vibegron (Obgemsa®) HTA ID: 24043
| Assessment Status | Rapid Review Complete |
| HTA ID | 24043 |
| Drug | Vibegron |
| Brand | Obgemsa® |
| Indication | Vibegron (Obgemsa®) is indicated for the symptomatic treatment of adult patients with overactive bladder syndrome. |
| Assessment Process | |
| Rapid review commissioned | 11/10/2024 |
| Rapid review completed | 26/11/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that vibegron not be considered for reimbursement at the submitted price*. |
*This recommendation is considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Voclosporin (Lupkynis®). HTA ID: 23003
| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23003 |
| Drug | Voclosporin |
| Brand | Lupkynis® |
| Indication | Voclosporin is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN). |
| Assessment Process | |
| Rapid review commissioned | 10/01/2023 |
| Rapid review completed | 10/02/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of voclosporin compared with the current standard of care. |
| Full HTA commissioned by the HSE | 01/03/2023 |
| Pre-submission consultation with Applicant | 23/05/2023 |
| Full submission received from Applicant | 20/09/2023 |
| Preliminary review sent to Applicant | 24/04/2024 |
| NCPE assessment re-commenced | 31/05/2024 |
| Follow-up to preliminary review sent to Applicant | 02/09/2024 |
| NCPE assessment re-commenced | 09/09/2024 |
| Factual accuracy sent to Applicant | 25/10/2024 |
| NCPE assessment re-commenced | 05/11/2024 |
| NCPE assessment completed | 05/12/2024 |
| NCPE assessment outcome | The NCPE recommends that voclosporin (Lupkynis®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. October 2025
Vosoritide (Voxzogo®). HTA ID: 22028
| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22028 |
| Drug | Vosoritide |
| Brand | Voxzogo® |
| Indication | For the treatment of genetically confirmed achondroplasia in patients aged two years and older whose epiphyses are not closed. |
| Assessment Process | |
| Rapid review commissioned | 09/05/2022 |
| Rapid review completed | 01/06/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of vosoritide compared with the current standard of care. |
| Full HTA commissioned by the HSE | 01/07/2022 |
| Pre-submission consultation with Applicant | 26/09/2022 |
| Full submission received from Applicant | 21/03/2023 |
| Preliminary review sent to Applicant | 24/07/2023 |
| NCPE assessment re-commenced | 22/08/2023 |
| Factual accuracy sent to Applicant | 13/09/2023 |
| NCPE assessment re-commenced | 22/09/2023 |
| NCPE assessment completed | 05/10/2023 |
| NCPE assessment outcome | Due to the paucity of clinical outcome data, the very high cost and budget impact in addition to the failure to demonstrate cost-effectiveness the NCPE Review Group recommend that vosoritide not be considered for reimbursement* |
*This recommendation should be considered while also having regards to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Zanubrutinib (Brukinsa®) for marginal zone lymphoma. HTA ID: 23072
| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23072 |
| Drug | Zanubrutinib |
| Brand | Brukinsa® |
| Indication | Zanubrutinib monotherapy is indicated for adult patients with relapsed/refractory marginal zone lymphoma with at least one prior anti-CD20-based therapy. |
| Assessment Process | |
| Rapid review commissioned | 01/12/2023 |
| Rapid review completed | 09/01/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of zanubrutinib compared with the current standard of care. |
| Full HTA commissioned by the HSE | 31/01/2024 |
| Pre-submission consultation with Applicant | 12/03/2024 |
| Full submission received from Applicant | 20/08/2024 |
| Preliminary review sent to Applicant | 23/05/2025 |
| NCPE assessment re-commenced | 20/06/2025 |
| Follow-up to preliminary review sent to Applicant | 08/07/2025 |
| NCPE assessment re-commenced | 10/07/2025 |
| Factual accuracy sent to Applicant | 30/07/2025 |
| NCPE assessment re-commenced | 08/08/2025 |
| NCPE assessment completed | 03/09/2025 |
| NCPE assessment outcome | The NCPE recommends that zanubrutinib not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Zolbetuximab (Vyloy®). HTA ID: 26029
| Assessment Status | Rapid Review Complete |
| HTA ID | 26029 |
| Drug | Zolbetuximab |
| Brand | Vyloy® |
| Indication | Zolbetuximab (Vyloy®) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive. |
| Assessment Process | |
| Rapid review commissioned | 23/06/2026 |
| Rapid review completed | 30/07/2026 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost-effectiveness of zolbetuximab (Vyloy®) compared with the current standard of care. |